| Mrs Christine Lorraine Knudsvig, ACNP-BC, FNP-BC | |
|
701 1st Street Sw, Crosby, ND 58730 | |
| (701) 965-6349 | |
| (701) 965-6407 |
| Full Name | Mrs Christine Lorraine Knudsvig |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 16 Years |
| Location | 701 1st Street Sw, Crosby, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134202559 | NPI | - | NPPES |
| 1466445 | Medicaid | ND |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital | Crosby, ND | Hospital |
| Trinity Hospitals | Minot, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes Hospital | 4486565645 | 4 |
News Archive
Disparities in healthcare between races exist in the United States. A new study published in the journal Transfusion explores why African Americans donate blood at lower rates than whites. The findings reveal that there is a significant distrust in the healthcare system among the African American community, and African Americans who distrust hospitals are less likely to donate.
Four years ago, when meningitis B, an extremely rare but potentially lethal form of the infection, sickened a small number of college students at Princeton and the University of California-Santa Barbara, there was no vaccine against the disease sold in the U.S. Despite its availability abroad, it had never been licensed in the country due to its limited marketability.
Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
› Verified 9 days ago
| Entity Name | St Lukes Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184737231 PECOS PAC ID: 4486565645 Enrollment ID: O20040423001224 |
News Archive
Disparities in healthcare between races exist in the United States. A new study published in the journal Transfusion explores why African Americans donate blood at lower rates than whites. The findings reveal that there is a significant distrust in the healthcare system among the African American community, and African Americans who distrust hospitals are less likely to donate.
Four years ago, when meningitis B, an extremely rare but potentially lethal form of the infection, sickened a small number of college students at Princeton and the University of California-Santa Barbara, there was no vaccine against the disease sold in the U.S. Despite its availability abroad, it had never been licensed in the country due to its limited marketability.
Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Christine Lorraine Knudsvig, ACNP-BC, FNP-BC 701 1st Street Sw, Crosby, ND 58730 Ph: (701) 965-6349 | Mrs Christine Lorraine Knudsvig, ACNP-BC, FNP-BC 701 1st Street Sw, Crosby, ND 58730 Ph: (701) 965-6349 |
News Archive
Disparities in healthcare between races exist in the United States. A new study published in the journal Transfusion explores why African Americans donate blood at lower rates than whites. The findings reveal that there is a significant distrust in the healthcare system among the African American community, and African Americans who distrust hospitals are less likely to donate.
Four years ago, when meningitis B, an extremely rare but potentially lethal form of the infection, sickened a small number of college students at Princeton and the University of California-Santa Barbara, there was no vaccine against the disease sold in the U.S. Despite its availability abroad, it had never been licensed in the country due to its limited marketability.
Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
› Verified 9 days ago
Janie Sova, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 702 1st St Sw, Crosby, ND 58730 Phone: 701-965-6349 | |
Jean M Nygaard, RNFNP PAC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 112 1st Ave Nw, Crosby, ND 58730 Phone: 701-965-6349 |